Page 46 - Read Online

Page 12 of 17 Nasr et al. Metab Target Organ Damage 2023;3:19 https://dx.doi.org/10.20517/mtod.2023.20

25. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc 1980;55:434-8. PubMed
26. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. a clinical and histologic comparison with alcohol-
induced liver injury. Gastro 1988;95:1056-62. PubMed
27. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594-8. DOI PubMed
28. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut
2004;53:750-5. DOI PubMed PMC
29. Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for
the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver
disease. Obes Facts 2016;9:65-90. DOI PubMed PMC
30. Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver.
EASL clinical practice guidelines: management of alcohol-related liver disease. J Hepatol 2018;69:154-81. DOI PubMed
31. Selin KH. Test-retest reliability of the alcohol use disorder identification test in a general population sample. Alcohol Clin Exp Res
2003;27:1428-35. DOI
32. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test
(AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II. Addiction 1993;88:791-
804. DOI PubMed
33. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective
brief screening test for problem drinking. ambulatory care quality improvement project (ACQUIP). alcohol use disorders
identification test. Arch Intern Med 1998;158:1789-95. DOI PubMed
34. Seitz HK. Additive effects of moderate drinking and obesity on serum gamma-glutamyl transferase. Am J Clin Nutr 2006;83:1252-3.
DOI PubMed
35. Gough G, Heathers L, Puckett D, et al. The utility of commonly used laboratory tests to screen for excessive alcohol use in clinical
practice. Alcohol Clin Exp Res 2015;39:1493-500. DOI PubMed PMC
36. Hock B, Schwarz M, Domke I, et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-
GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol
dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005;100:1477-86. DOI PubMed
37. Reynaud M, Schellenberg F, Loisequx-Meunier MN, Schwan R, Maradeix B, Planche F, Gillet C. Objective diagnosis of alcohol
abuse: compared values of carbohydrate-deficient transferrin (CDT), gamma-glutamyl transferase (GGT), and mean corpuscular
volume (MCV). Alcohol Clin Exp Res 2000;24:1414-9. PubMed
38. Staufer K, Andresen H, Vettorazzi E, Tobias N, Nashan B, Sterneck M. Urinary ethyl glucuronide as a novel screening tool in
patients pre- and post-liver transplantation improves detection of alcohol consumption. Hepatology 2011;54:1640-9. DOI PubMed
39. Helander A, Wielders J, Anton R, et al; International Federation of Clinical Chemistry and Laboratory Medicine Working Group on
Standardisation of Carbohydrate-Deficient Transferrin (IFCC WG-CDT). Standardisation and use of the alcohol biomarker
carbohydrate-deficient transferrin (CDT). Clin Chim Acta 2016;459:19-24. DOI
40. Niemelä O. Biomarker-based approaches for assessing alcohol use disorders. Int J Environ Res Public Health 2016;13:166. DOI
PubMed PMC
41. Anton RF, Lieber C, Tabakoff B. Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring
of alcohol use: results from a multisite study. Alcoholism Clin Exp Res 2002;26:1215-22. DOI PubMed
42. Anton RF. Carbohydrate-deficient transferrin for detection and monitoring of sustained heavy drinking. what have we learned?
Alcohol 2001;25:185-8. DOI PubMed
43. Hartmann S, Aradottir S, Graf M, et al. Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl
transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addict Biol 2007;12:81-4. DOI PubMed
44. Schröck A, Thierauf-Emberger A, Schürch S, Weinmann W. Phosphatidylethanol (PEth) detected in blood for 3 to 12 days after
single consumption of alcohol-a drinking study with 16 volunteers. Int J Legal Med 2017;131:153-60. DOI PubMed
45. Kechagias S, Dernroth DN, Blomgren A, et al. Phosphatidylethanol compared with other blood tests as a biomarker of moderate
alcohol consumption in healthy volunteers: a prospective randomized study. Alcohol Alcohol 2015;50:399-406. DOI
46. Walther L, de Bejczy A, Löf E, et al. Phosphatidylethanol is superior to carbohydrate-deficient transferrin and γ-glutamyltransferase
as an alcohol marker and is a reliable estimate of alcohol consumption level. Alcohol Clin Exp Res 2015;39:2200-8. DOI PubMed
47. Long MT, Massaro JM, Hoffmann U, Benjamin EJ, Naimi TS. Alcohol use is associated with hepatic steatosis among persons with
presumed nonalcoholic fatty liver disease. Clin Gastroenterol H 2020;18:1831-1841.e5. DOI PubMed PMC
48. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med
2000;132:112-7. DOI
49. Lau K, Baumeister SE, Lieb W, et al. The combined effects of alcohol consumption and body mass index on hepatic steatosis in a
general population sample of European men and women. Aliment Pharmacol Ther 2015;41:467-76. DOI
50. Staufer K, Huber-Schönauer U, Strebinger G, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in
presumed non-alcoholic fatty liver disease. J Hepatol 2022;77:918-30. DOI
51. Dunn W, Sanyal AJ, Brunt EM, et al. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in
patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012;57:384-91. DOI PubMed PMC